Infant Bacterial Therapeutics
54.8
SEK
-2.66 %
Less than 1K followers
IBT B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
Infant Bacterial Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory bowel diseases. The company develops, among other things, medicines to treat and prevent common conditions and diseases in children that occur at early birth. The business is global with a primary presence in Europe and North America. Infant Bacterial Therapeutics was founded in 2011 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
738.23M SEK
Turnover
581.31K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
20/8
2025
Interim report Q2'25
13/11
2025
Interim report Q3'25
All
Press releases
ShowingAll content types
Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki
Årsstämma i Infant Bacterial Therapeutics
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools